Your browser doesn't support javascript.
loading
Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR.
Klyuchnikov, Evgeny; Langebrake, Claudia; Badbaran, Anita; Dadkhah, Adrin; Massoud, Radwan; Freiberger, Petra; Ayuk, Francis; Janson, Dietlinde; Wolschke, Christine; Bacher, Ulrike; Kröger, Nicolaus.
  • Klyuchnikov E; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Langebrake C; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Badbaran A; Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Dadkhah A; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Massoud R; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Freiberger P; Hospital Pharmacy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Ayuk F; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Janson D; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Wolschke C; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Bacher U; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
  • Kröger N; Department of Stem Cell Transplantation, University Medical Center Eppendorf, University of Hamburg, Hamburg, Germany.
Eur J Haematol ; 110(2): 188-197, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36335432

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Trasplante de Células Madre Hematopoyéticas / Enfermedad Injerto contra Huésped Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article